Moderna and Merck announced detailed phase 3 trial results for intismeran autogene, their personalized mRNA-based cancer vaccine, on Thursday, following partial data that leaked on social media earlier that day [1]. The vaccine, when combined with Merck's immunotherapy Keytruda, demonstrated clinically significant efficacy in melanoma treatment: it reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone, and reduced the risk of cancer spreading to distant parts of the body or death by 38%, based on a trial of approximately 1,100 patients whose tumors had been surgically removed [1].
A secondary analysis revealed more encouraging signals in the later stages of treatment, showing the combination reduced recurrence or death risk by 58% after the six-month mark, compared with Keytruda alone, though the median follow-up was approximately two years at the time of analysis [1]. The 42% overall result reflects the treatment effect throughout the entire trial follow-up period [1]. Six melanoma specialists interviewed by CNBC characterized the results as representing a clinically meaningful advance that could potentially become a standard of care for melanoma patients who have undergone surgery and have not previously received immunotherapy [1].
Clinical experts emphasized the significance of these findings. Dr. Sekwon Jang, a melanoma specialist at Inova Schar Cancer and principal investigator at a trial site, stated: "This has the potential to be a major breakthrough in melanoma treatment and also cancer immunotherapy in general that will open the door to greater outcomes for patients" [1]. Dr. Janice Mehnert from NYU Langone noted that "this is the first time we're seeing that when you add something to immunotherapy, you actually boost the efficacy of the immunotherapy" [1]. The vaccine functions as a personalized treatment, training the immune system to recognize and attack residual cancer cells based on specific mutations in an individual patient's tumor, working synergistically with Keytruda's immune-activating mechanism [1].
The clinical importance of preventing melanoma recurrence is substantial, as the disease becomes significantly more difficult to treat once it returns after surgery and spreads to distant sites such as the lungs, brain, or liver [1]. Patients with advanced disease may require additional treatments including immunotherapy, radiation, or further surgery, with no guarantee of success [1]. Despite the medical community's enthusiasm for these results, the headline notes that Wall Street's reaction has been more muted, suggesting potential market skepticism regarding commercial viability or other factors [1].
CONCLUSION
Moderna and Merck's intismeran autogene vaccine demonstrated a 42% reduction in melanoma recurrence or death risk when combined with Keytruda, with even stronger 58% risk reduction after six months, representing what clinical specialists describe as a potential breakthrough in cancer immunotherapy [1]. While the medical community has responded positively to these phase 3 results, the market reaction has been notably subdued, indicating investor concerns may extend beyond the clinical efficacy data [1].